Small text size

Medium text size

Large text size

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

Click on the slide!

Driven by Science

Rapid, efficient, cost-effective approach

Our expert team is skilled at identifying promising drug candidates and advancing them through all stages of drug development.

Click on the slide!

Focused on Life

Developing novel small molecule drugs for serious diseases

We aim to transform the treatment of cancer and offer hope to patients and their caregivers.

Click on the slide!

Enzalutamide

(formerly MDV3100) First in class, oral androgen receptor signaling inhibitor (ARSI) candidate in Phase 3 development

News & Recent Releases

Medivation © 2012